The oncology software developed by the Hungarian start-up company provides artificial intelligence (AI) based digital therapy planning. It facilitates the selection of the most suitable and efficient targeted treatment by organizing and weighting scientific evidence in a predictive way.
With the help of molecular diagnostics, the company establishes a detailed molecular profile (comprehensive diagnostic panels) and determines the molecular point of attack for targeted therapies. Then recommends the comprehensive molecular profile tests to oncologists.
During therapy planning supported by digital devices, the medical team reviews and captures the patient’s medical history and enters the results of the molecular diagnostic tests of the patient’s tumor into this online decision support system. If these tests are not available or are proven to be insufficient, the necessary molecular diagnostic tests will be performed. The results are analyzed by the molecular biologists or info-bionic experts using the oncology software. The results of the analysis will be discussed at an online video conference by a special board of experts, called the virtual molecular tumor board (VMTB) – consisting of oncologists, molecular biologists and geneticists. In accordance with the recommendation of the experts or upon the request of the treating physician, the treating physician may also participate in the expert meeting. Based on the VMTB’s recommendation, a patient-specific digital therapy plan is created, which is used by the treating physician for the therapeutic decision.
It has been developed for oncologists, publicly and privately funded oncology institutions and insurance companies.
The company is looking for partners under commercial agreement with technical assistance to support the transfer of the technology with the provision of additional support services. It is also open to have a licence agreement with licensee partners.
